By activating GIP receptors alongside GLP-1 receptors simultaneously, tirzepatide creates synergistic metabolic effects that exceed what either hormone achieves alone
USP Pharmaceutical Compounding, Sterile Preparations
This product is not for human consumption, medical, therapeutic, or diagnostic use
Apart from gastrointestinal symptoms, Semaglutide may cause changes in appetite and weight loss, which are generally considered beneficial in patients with type 2 diabetes, especially those who are overweight or obese
Customized Programs: Based on your unique medical history and metabolic markersnot a generic template
Switching from Ozempic to Wegovy will be a positive for many people looking to lose weight in the long term